Antimicrobial resistance in Mycoplasma genitalium sampled from the British general populationShow others and affiliations
2020 (English)In: Sexually Transmitted Infections, ISSN 1368-4973, E-ISSN 1472-3263, Vol. 96, no 6, p. 464-468Article in journal (Refereed) Published
Abstract [en]
Background: Mycoplasma genitaliumis a common sexually transmitted infection. Treatment guidelines focus on those with symptoms and sexual contacts, generally with regimens including doxycycline and/or azithromycin as first-line and moxifloxacin as second-line treatment. We investigated the prevalence of antimicrobial resistance (AMR)-conferring mutations inM. genitaliumamong the sexually-active British general population.
Methods: The third national survey of sexual attitudes and lifestyles (Natsal-3) is a probability sample survey of 15 162 men and women aged 16-74 years in Britain conducted during 2010-12. Urine test results forM. genitaliumwere available for 4507 participants aged 16-44 years reporting>1 lifetime sexual partner. In this study, we sequenced regions of the 23S rRNA andparCgenes to detect known genotypic determinants for resistance to macrolides and fluoroquinolones respectively.
Results: 94% (66/70) of specimens were re-confirmed asM. genitaliumpositive, with successful sequencing in 85% (56/66) for 23S rRNA and 92% (61/66) forparCgenes. Mutations in 23S rRNA gene (position A2058/A2059) were detected in 16.1% (95%CI: 8.6% to 27.8%) and inparC(encodingParCD87N/D87Y) in 3.3% (0.9%-11.2%). Macrolide resistance was more likely in participants reporting STI diagnoses (past 5 years) (44.4% (18.9%-73.3%) vs 10.6% (4.6%-22.6%); p=0.029) or sexual health clinic attendance (past year) (43.8% (23.1%-66.8%) vs 5.0% (1.4%-16.5%); p=0.001). All 11 participants with AMR-conferring mutations had attended sexual health clinics (past 5 years), but none reported recent symptoms.
Conclusions: This study highlights challenges inM. genitaliummanagement and control. Macrolide resistance was present in one in six specimens from the general population in 2010-2012, but no participants with AMRM. genitaliumreported symptoms. Given anticipated increases in diagnostic testing, new strategies including novel antimicrobials, AMR-guided therapy, and surveillance of AMR and treatment failure are recommended.
Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2020. Vol. 96, no 6, p. 464-468
Keywords [en]
Mycoplasma genitalium, antibiotic resistance, molecular epidemiology, mycoplasma, public health
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-78962DOI: 10.1136/sextrans-2019-054129ISI: 000566988500017PubMedID: 31924741Scopus ID: 2-s2.0-85087943534OAI: oai:DiVA.org:oru-78962DiVA, id: diva2:1385566
Funder
Wellcome trust
Note
Funding Agencies:
Medical Research Council UK (MRC) G0701757
Economic & Social Research Council (ESRC)
Department of Health
2020-01-142020-01-142020-12-01Bibliographically approved